OTCMKTS:AGNPF Algernon Pharmaceuticals (AGNPF) Stock Price, News & Analysis $0.30 -0.02 (-5.76%) As of 10/13/2026 11:25 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Algernon Pharmaceuticals Stock (OTCMKTS:AGNPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AGNPF alerts:Sign Up Key Stats Today's Range$0.30▼$0.3050-Day Range$0.25▼$0.4252-Week Range$0.22▼$0.64Volume304 shsAverage Volume8,797 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Algernon Pharmaceuticals Inc. is a Canadian clinical-stage pharmaceutical development company focused on discovering and advancing therapeutics for diseases with significant unmet medical needs. The company has primarily pursued a drug-repurposing strategy, evaluating existing compounds for potential applications in respiratory, neurological and other serious conditions. Algernon’s development programs have included NP-120, an extended-release formulation of ifenprodil. The company has investigated ifenprodil as a potential treatment for conditions including idiopathic pulmonary fibrosis, chronic cough and ischemic stroke, and has also evaluated the compound in connection with respiratory disease research. Its programs have included preclinical and clinical studies conducted through company subsidiaries and research partners. Headquartered in Vancouver, British Columbia, Algernon has historically worked with international research organizations and clinical investigators to advance its pharmaceutical candidates. The company’s leadership has included Christopher J. Moreau as chief executive officer. Algernon’s pipeline and corporate priorities may change as clinical data and regulatory discussions develop.AI Generated. May Contain Errors. Read More Receive AGNPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGNPF Stock News HeadlinesAlgernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Stock Short Interest Falls 36.6%October 3, 2026 | americanbankingnews.comGrey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 MillionSeptember 16, 2026 | globenewswire.comFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.October 14 at 1:00 AM | Monetary Gold (Ad)Grey Matters Achieves Final Major Milestone; Receives Radioactive Materials License from State of Florida for its Flagship NovaScan Neuroimaging Clinics™ LocationAugust 20, 2026 | globenewswire.comGrey Matters Announces CAD $800K of Private Placement Equity Financing and Convertible DebenturesAugust 20, 2026 | globenewswire.comGrey Matters Retains Nationally Recognized ProScan to Read Brain Images from its Flagship NovaScan Neuroimaging Clinics™ Location in FloridaAugust 19, 2026 | globenewswire.comGrey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.August 4, 2026 | globenewswire.comGrey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in FloridaJuly 6, 2026 | globenewswire.comSee More Headlines AGNPF Stock Analysis - Frequently Asked Questions How have AGNPF shares performed this year? Algernon Pharmaceuticals' stock was trading at $0.05 at the start of the year. Since then, AGNPF stock has increased by 502.4% and is now trading at $0.3012. When did Algernon Pharmaceuticals' stock split? Algernon Pharmaceuticals shares split on the morning of Friday, March 3rd 2023.The 4-1 split was announced on Friday, March 3rd 2023. The newly issued shares were distributed to shareholders after the market closes on Friday, March 3rd 2023. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. How do I buy shares of Algernon Pharmaceuticals? Shares of AGNPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/14/2026Next Earnings (Estimated)12/18/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:AGNPF CIK1642178 Webalgernonpharmaceuticals.com Phone604-398-4175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:AGNPF) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Algernon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
